Kyntra Bio Inc (KYNB) vs NextCure, Inc. (NXTC)
Kyntra Bio Inc and NextCure, Inc. are both Biotechnology companies. Kyntra Bio Inc is the larger, with a market value of $28.3M against $25.4M — 1.1× the size. NextCure, Inc. has negative trailing earnings, so its P/E is not meaningful; Kyntra Bio Inc trades at 0.2×. Kyntra Bio Inc has the higher net margin (3,967.8% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Kyntra Bio Inc leads on 7 and NextCure, Inc. on 6.
Valuation
Profitability
| Metric | KYNB | NXTC | Biotechnology median |
|---|---|---|---|
| Gross margin | 6.28% | 0.00% | 65.16% |
| Operating margin | (1,089.78%) | 0.00% | 0.00% |
| Net margin | 3,967.77% | 0.00% | 0.00% |
| Free cash flow margin | (824.19%) | 0.00% | 0.00% |
| Return on equity | (157.83%) | (195.22%) | (57.72%) |
| Return on assets | 131.26% | (121.60%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack